论文部分内容阅读
目的 探讨扎鲁司特对哮喘患者的疗效和安全性。方法 对３９０ 例哮喘患者进行开放性、非对照、多中心研究， 观察病人用药前及用药后肺功能、哮喘自觉症状、不良反应。结果 扎鲁司特使病人的ＦＥＶ１ 由治疗前的２－１１Ｌ 上升至治疗后２－２８Ｌ， 晨间ＰＥＦ（ＰＥＦａｍ） 从３１５－２２Ｌ／ｍｉｎ 升至３５０－２７Ｌ／ｍｉｎ， 上述肺功能及用药后哮喘症状评分、夜间憋醒次数、无症状天数、吸入性β２ 受体激动剂用量与用药前相比， 均明显改善， Ｐ＜ ０－０１。可疑药物不良反应发生率２－１％ ， 主要是消化道不适和头痛。结论 扎鲁司特可提高哮喘患者的肺功能， 改善哮喘症状， 具有良好的安全性。
Objective To investigate the efficacy and safety of zafirlukast in patients with asthma. Methods Open, uncontrolled and multicenter studies were performed on 390 asthmatic patients. Lung function, asthma symptoms and adverse reactions were observed before and after treatment. Results The patient’s FEV1 increased from 2-11L before treatment to 2-28L after treatment. The morning PEF (PEFam) increased from 315-22L / min to 350-27L / min. The above-mentioned pulmonary function and asthma after treatment Symptom score, nighttime arousal, asymptomatic days, inhaled β2 agonist dosage were significantly improved compared with before treatment, P <0-01. The incidence of suspected adverse drug reactions 2-1%, mainly gastrointestinal discomfort and headache. Conclusion Zafirlukast can improve the lung function of asthmatic patients and improve asthma symptoms, with good safety.